Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM and NLMIXED

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 31, Issue 4, 2004, Pages 299-320

  Jönsson, Siv ^a   Kjellsson, Maria C ^a   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

bias in parameter estimates; Gaussian quadrature; Laplacian; maximum likelihood estimation; NLMIXED; NONMEM; ordered categorical; proportional odds model; SAS

Indexed keywords

ARTICLE; BAYES THEOREM; MATHEMATICAL MODEL; MONTE CARLO METHOD; NORMAL DISTRIBUTION; POPULATION; PRIORITY JOURNAL;

BIAS (EPIDEMIOLOGY); LIKELIHOOD FUNCTIONS; MODELS, BIOLOGICAL; MONTE CARLO METHOD;

EID: 4644304156     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:JOPA.0000042738.06821.61     Document Type: Article

References (25)

1. A. Agresti. Modelling ordered categorical data: recent advances and future challenges. Stat. Med. 18:2191-2207 (1999).
2. R. Stiratelli, N. Laird, and J. H. Ware. Random-effects models for serial observations with binary response. Biometrics 40:961-971 (1984).
3. D. A. Harville, and R. W. Mee. A mixed-model procedure for analysing ordered categorical data. Biometrics 40:393-408 (1984).
4. L. B. Sheiner. A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data. Clin. Pharmacol. Ther. 56:309-322 (1994).
5. F. Ezzet, and J. Whitehead. A random effects model for ordinal responses from a cross-over trial. Stat Med. 10:901-6 ; discussion 906-7 (1991).
6. C. A. Knibbe, K. P. Zuideveld, J. Dejongh, P. F. Kuks, L. P. Aarts, and M. Danhof. Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. Clin. Pharmacol. Ther. 72:670-684 (2002).
7. S. K. Gupta, G. Sathyan, E. A. Lindemulder, P. L. Ho, L. B. Sheiner, and L. Aarons. Quantitative characterization of therapeutic index: application of mixed-effects modeling to evaluate oxybutynin dose-efficacy and dose-side effect relationships. Clin. Pharmacol. Ther. 65:672-684 (1999).
8. X. Lin and N. E. Breslow. Bias correction in generalized linear mixed models with multiple components of dispersion. J. Am. Stat. Assoc. 91:1007-1016 (1996).
9. G. Rodriguez and N. Goldman. An assessment of estimation procedures for multilevel models with binary responses. J R Stat. Soc A. 158:73-89 (1995).
10. N. H. Holford, H. C. Kimko, J. P. Monteleone, and C. C. Peck. Simulation of clinical trials. Annu. Rev. Pharmacol. Toxicol. 40:209-234 (2000).
11. S. Chabaud, P. Girard, P. Nony, and J. P. Boissel. Clinical trial simulation using therapeutic effect modeling: application to ivabradine efficacy in patients with angina pectoris. J. Pharmacokinet. Pharmacodyn. 29:339-363 (2002).
12. S. L. Beal and L. B. Sheiner NONMEM Users Guides. Hanover, Maryland: GloboMax, Inc., 1989-1998.
13. D. J. Lunn, J. Wakefield, and A. Racine Poon. Cumulative logit models for ordinal data: A case study involving allergic rhinitis severity scores. Stat. Med. 20:2261-2285 (2001).
14. D. R. Mould, N. H. Holford, J. H. Schellens, J. H. Beijnen, P. R. Hutson, H. Rosing, W. W. tenBokkel Huinink, E. K. Rowinsky, J. H. Schiller, M. Russo, and G. Ross. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors. Clin. Pharmacol. Ther. 71:334-348 (2002).
15. L. Aarons and G. Graham. Methodological approaches to the population analysis of toxicity data. Toxicol. Lett. 120:405-410 (2001).
16. I. Nestorov, G. Graham, S. Duffull, L. Aarons, E. Fuseau, and P. Coates. Modeling and simulation for clinical trial design involving a categorical response: a phase II case study with naratriptan. Pharm. Res. 18:1210-1219 (2001).
17. J. W. Mandema and D. R. Stanski. Population pharmacodynamic model for ketorolac analgesia. Clin. Pharmacol. Ther. 60:619-635 (1996).
18. S. L. Beal, and L. B. Sheiner NONMEM Users Guide - Part VII:Conditional Estimation Methods. GloboMax, Inc., Hanover, Maryland, 1992-1998.
19. J. C. Pinheiro and D. M. Bates. Approximations to the log-likelihood function in the nonlinear mixed-effects model. J. Comput. Graph. Stat. 4:12-35 (1995).
20. SAS Institute Inc SAS Online Doc, SAS/STAT User's Guide, The NLMIXED Procedure. http://statdist.its.uu.se/sas/SASOnlinedocV8/sasdoc/saspdf/.
21. J. Wakefield and S. Walker. A population approach to initial dose selection. Stat. Med. 16:1135-1149 (1997).
22. M. O. Karlsson, E. N. Jonsson, C. G. Wiltse, and J. R. Wade. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J. Pharmacokinet. Biopharm. 26:207-246 (1998).
23. M. C. Kjellsson, S. Jönsson, and M. O. Karlsson The Back-Step Method-Method for Obtaining Unbiased Population Parameter Estimates for Ordered Categorical Data, AAPS J. 6:article 19, (2004).
24. S. Jonsson and M. O. Karlsson. Estimating bias in parameters for some NONMEM models for ordered categorical data. http://www.page-meeting.org/ (2002).
25. K. G. Kowalski, L. McFadyen, M. M. Hutmacher, B. Frame, and R. Miller. A two-part mixture model for longitudinal adverse event severity data. J. Pharmacokinet. Pharmacodyn. 30:315-336 (2003).